Recent Investment Analysts’ Ratings Updates for Apogee Therapeutics (APGE)

Apogee Therapeutics (NASDAQ: APGE) has recently received a number of price target changes and ratings updates:

• 11/27/2024 – Apogee Therapeutics had its price target raised by analysts at Guggenheim from $95.00 to $110.00. They now have a “buy” rating on the stock.
• 11/25/2024 – Apogee Therapeutics is now covered by analysts at Canaccord Genuity Group Inc.. They set a “buy” rating and a $89.00 price target on the stock.
• 11/25/2024 – Apogee Therapeutics is now covered by analysts at Canaccord Genuity Group Inc.. They set a “buy” rating and a $89.00 price target on the stock.
• 11/12/2024 – Apogee Therapeutics had its “outperform” rating reaffirmed by analysts at Wedbush. They now have a $87.00 price target on the stock.
• 10/25/2024 – Apogee Therapeutics had its “outperform” rating reaffirmed by analysts at Wedbush. They now have a $87.00 price target on the stock.

Apogee Therapeutics Price Performance

NASDAQ:APGE traded up $0.60 during mid-day trading on Wednesday, reaching $44.56. The stock had a trading volume of 401,429 shares, compared to its average volume of 493,998. The stock has a market cap of $2.01 billion, a P/E ratio of -18.41 and a beta of 2.93. The business’s 50 day moving average is $54.01 and its 200 day moving average is $48.57. Apogee Therapeutics, Inc. has a fifty-two week low of $16.39 and a fifty-two week high of $72.29.

Insiders Place Their Bets

In other Apogee Therapeutics news, CEO Michael Thomas Henderson sold 40,000 shares of the company’s stock in a transaction dated Wednesday, October 2nd. The shares were sold at an average price of $56.23, for a total transaction of $2,249,200.00. Following the completion of the sale, the chief executive officer now directly owns 1,354,487 shares in the company, valued at $76,162,804.01. This represents a 2.87 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Carl Dambkowski sold 6,665 shares of Apogee Therapeutics stock in a transaction dated Wednesday, September 4th. The stock was sold at an average price of $47.56, for a total value of $316,987.40. Following the completion of the transaction, the insider now owns 280,793 shares in the company, valued at $13,354,515.08. The trade was a 2.32 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 114,995 shares of company stock valued at $6,128,295 over the last quarter. Insiders own 36.10% of the company’s stock.

Institutional Trading of Apogee Therapeutics

A number of hedge funds have recently bought and sold shares of the stock. Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in shares of Apogee Therapeutics during the third quarter valued at approximately $71,000. Mirae Asset Global Investments Co. Ltd. increased its holdings in Apogee Therapeutics by 21.2% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,628 shares of the company’s stock valued at $94,000 after buying an additional 285 shares during the period. Allspring Global Investments Holdings LLC bought a new stake in Apogee Therapeutics in the 2nd quarter valued at $143,000. Kennedy Capital Management LLC bought a new position in shares of Apogee Therapeutics during the 1st quarter worth about $212,000. Finally, Wexford Capital LP acquired a new stake in shares of Apogee Therapeutics during the 3rd quarter valued at about $230,000. 79.04% of the stock is owned by institutional investors.

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.